TW202203936A - 啟動內源性抗菌藥物治療sars-cov-2感染 - Google Patents

啟動內源性抗菌藥物治療sars-cov-2感染 Download PDF

Info

Publication number
TW202203936A
TW202203936A TW110112408A TW110112408A TW202203936A TW 202203936 A TW202203936 A TW 202203936A TW 110112408 A TW110112408 A TW 110112408A TW 110112408 A TW110112408 A TW 110112408A TW 202203936 A TW202203936 A TW 202203936A
Authority
TW
Taiwan
Prior art keywords
hydroxyvitamin
day
subject
compared
days
Prior art date
Application number
TW110112408A
Other languages
English (en)
Chinese (zh)
Inventor
查理斯 W 畢夏普
史蒂芬 A 史特拉格奈爾
阿克塔 阿許法克
瑞姆 阿萊曼 艾賽迪格
克曼 奈堤
Original Assignee
愛爾蘭商艾爾根製藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 愛爾蘭商艾爾根製藥有限公司 filed Critical 愛爾蘭商艾爾根製藥有限公司
Publication of TW202203936A publication Critical patent/TW202203936A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
TW110112408A 2020-04-06 2021-04-06 啟動內源性抗菌藥物治療sars-cov-2感染 TW202203936A (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US202063006034P 2020-04-06 2020-04-06
US63/006,034 2020-04-06
US202063006563P 2020-04-07 2020-04-07
US63/006,563 2020-04-07
US202063009155P 2020-04-13 2020-04-13
US63/009,155 2020-04-13
US202063012781P 2020-04-20 2020-04-20
US63/012,781 2020-04-20
US202063032714P 2020-05-31 2020-05-31
US63/032,714 2020-05-31

Publications (1)

Publication Number Publication Date
TW202203936A true TW202203936A (zh) 2022-02-01

Family

ID=75904967

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110112408A TW202203936A (zh) 2020-04-06 2021-04-06 啟動內源性抗菌藥物治療sars-cov-2感染

Country Status (8)

Country Link
US (2) US20210308151A1 (cg-RX-API-DMAC7.html)
EP (1) EP4132477A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023520591A (cg-RX-API-DMAC7.html)
KR (1) KR20220164539A (cg-RX-API-DMAC7.html)
CN (1) CN116033940A (cg-RX-API-DMAC7.html)
CA (1) CA3176559A1 (cg-RX-API-DMAC7.html)
TW (1) TW202203936A (cg-RX-API-DMAC7.html)
WO (1) WO2021205225A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2862462B2 (es) * 2020-04-06 2023-04-27 Servicio Andaluz De Salud Compuestos para la profilaxis y/o el tratamiento del sindrome de dificultad respiratoria aguda
CA3181945A1 (en) * 2020-05-31 2021-12-09 Eirgen Pharma Ltd. Hard capsule dosage form and uses thereof
CN116785295A (zh) * 2023-06-29 2023-09-22 吉林大学 雷特格韦在防治新型冠状病毒感染药物中的应用
WO2025094144A1 (en) 2023-11-02 2025-05-08 Eirgen Pharma Ltd. Controlling loss of kidney function

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264223A (en) 1990-03-29 1993-11-23 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
US5431917A (en) 1992-10-08 1995-07-11 Japan Elanco Company, Ltd. Hard capsule for pharmaceutical drugs and method for producing the same
FR2757173A1 (fr) 1996-12-17 1998-06-19 Warner Lambert Co Compositions polymeres d'origine non-animale pour la formation de films
KR100379674B1 (ko) 2000-03-06 2003-04-10 주식회사 서흥캅셀 펙틴과 글리세린의 배합용액을 이용한 셀룰로오스 캅셀 및그의 제조방법
PT3095447T (pt) * 2006-02-03 2022-01-24 Opko Renal Llc Tratamento da insuficiência e deficiência de vitamina d com 25-hidroxivitamina d2 e 25-hidroxivitamina d3
CA2651283A1 (en) 2006-05-15 2007-11-22 Wisconsin Alumni Research Foundation Pulmonary delivery of 1.alpha.,25-dihydroxyvitamin d3 and co-administration of parathyroid hormone or calcitonin
FR2902092B1 (fr) 2006-06-07 2008-09-05 Sapelem Soc Par Actions Simpli Appareil de manutention de charge
KR101691876B1 (ko) * 2007-04-25 2017-01-02 사이토크로마 인코포레이티드 비타민 d 화합물과 밀랍성 담체를 포함하는 경구 조절성 방출 조성물
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 d 방출 제형
CR20170085A (es) * 2014-08-07 2017-04-25 Opko Ireland Global Holdings Ltd Terapia adjuntiva con 25-hidroxi vitamina d
KR20180123100A (ko) * 2016-03-28 2018-11-14 옵코 아일랜드 글로벌 홀딩스 리미티드 비타민 d 치료 방법
EP3843706A1 (en) 2018-08-31 2021-07-07 OPKO Ireland Global Holdings, Ltd. Vitamin d pediatric dosage forms, methods of making and using

Also Published As

Publication number Publication date
WO2021205225A1 (en) 2021-10-14
US20250144119A1 (en) 2025-05-08
CA3176559A1 (en) 2021-10-14
US20210308151A1 (en) 2021-10-07
JP2023520591A (ja) 2023-05-17
WO2021205225A8 (en) 2023-01-05
CN116033940A (zh) 2023-04-28
KR20220164539A (ko) 2022-12-13
EP4132477A1 (en) 2023-02-15

Similar Documents

Publication Publication Date Title
US20250144119A1 (en) Activating endogenous antimicrobials to treat sars-cov-2 infection
TWI777515B (zh) 治療嗜伊紅性食道炎之方法
Hegarty et al. Thalidomide for the treatment of recalcitrant oral Crohn's disease and orofacial granulomatosis
JP2021514968A (ja) 微生物関連の免疫療法
US8080528B2 (en) Compositions and methods for treatment of cachexia
JP2019528272A5 (cg-RX-API-DMAC7.html)
KR20170026635A (ko) 장기 재생을 위한 내인성 회장 브레이크 호르몬 경로의 활성화 및 관련 조성물, 치료 방법, 진단법, 및 조절 시스템
US11857542B2 (en) Treatment of migraine
JP2020528928A (ja) ジピベフリンの使用方法
US20230330110A1 (en) Hard capsule dosage form and uses thereof
RU2586742C2 (ru) Композиция для лечения метаболических расстройств
CN113260363A (zh) 格拉普兰特(grapiprant)单位剂型
WO2021195119A1 (en) Methods of reducing the risk of, severity of, and treating coronavirus infections
TW202547505A (zh) 包含azd0780之醫藥組合物
JP2015504881A (ja) 胃腸感染および障害を処置するための医薬組成物および方法
TW201034704A (en) Delayed-release glucocorticoid treatment of rheumatoid arthritis by improving signs and symptoms, showing major or complete clinical response and by preventing from joint damage
KR20170086053A (ko) 디메틸 푸마르산염을 포함하는 제약학적 매트릭스 제제
CN120282773A (zh) 用于全肠外和肠内营养的具有抗炎作用的脂质乳剂
US20240009154A1 (en) Methods and compositions for treating cytokine release syndrome
JP2009067679A (ja) 抗ヒスタミン作用を有する医薬
EP4326279A1 (en) Universal dosage regime of 25-hydroxy vitamin d3
WO2021205049A1 (es) Compuestos para la profilaxis y/o el tratamiento del síndrome de dificultad respiratoria aguda
EP4415733A1 (fr) Combinaison d'e. faecalis et d'un agent anti-inflammatoire et ses utilisations dans la prevention et/ou traitement des maladies respiratoires
TW202143985A (zh) 治療之方法
TW200840590A (en) Compositions and methods for prevention and treatment of cachexia